Tomonari A, Iseki T, Asano S
Division of Molecular Therapy, Advanced Clinical Research Center, Institute of Medical Science, University of Tokyo.
Nihon Rinsho. 2001 Dec;59(12):2433-8.
Umbilical cord blood transplantation(CBT) from HLA-mismatched unrelated donors has been increasingly performed. One of the advantages of unrelated CBT is a low risk of severe acute graft-versus-host disease(aGVHD). The degree of HLA disparities is not strongly associated with the occurrence of severe aGVHD. The disadvantages of CBT include a delayed time of hematopoietic recovery and a high rate of graft failure, which are significantly associated with the lower number of infused cord blood cells. Despite a relatively high rate of early transplant-related mortality, cord blood cells from HLA-mismatched unrelated donors should be considered as an alternative hematopoietic stem source for both children and adults who have no suitable related and unrelated bone marrow donors. Further clinical and laboratory studies are needed to improve the outcome of CBT.
来自人类白细胞抗原(HLA)配型不合的无关供者的脐带血移植(CBT)已越来越多地开展。无关供者CBT的优势之一是严重急性移植物抗宿主病(aGVHD)风险低。HLA不相合程度与严重aGVHD的发生没有密切关联。CBT的缺点包括造血恢复时间延迟和移植物失败率高,这与输注的脐带血细胞数量较少显著相关。尽管早期移植相关死亡率相对较高,但对于没有合适的相关和无关骨髓供者的儿童和成人,HLA配型不合的无关供者的脐带血细胞应被视为一种替代造血干细胞来源。需要进一步开展临床和实验室研究以改善CBT的疗效。